English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

177 Lu-PSMA-617 therapeutic agent was prepared successfully under optimized condition of pH=4.5, molar ratio of metal to ligand 1:10, temperature of 95°C and 40 min reaction time.  177 LuCl 3  was obtained with specific activity of 70–80 GBq/mg by the thermal neutron irradiation (5×10 13  n cm −2  s −1 ) of the enriched Lu 2 O 3  (52%  176 Lu) samples. The radionuclidic purity of  177 LuCl 3  (&gt;99%) was checked by a HPGe detector. The radiochemical purities of  177 LuCl 3  solution and  177 Lu-PSMA-617 compound (&gt;98%) were checked by ITLC and HPLC techniques and stability studies were assayed in the presence of human serum. Biodistribution and imaging assessments in the breast adenocarcinoma-bearing mice showed a major accumulation of activity in the tumor and kidneys tissues, as the expression site of PSMA molecule and the main route of excretion, respectively.

Production, quality control, biodistribution and imaging studies of 177 Lu-PSMA-617 in breast adenocarcinoma model